title: Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?
authors.affiliation: Metabolic Medicine SpR, Imperial College London, London, UK.
authors.forename: Julia S
authors.initials: JS
authors.lastname: Kenkre
mesh_terms: D004164:Diphosphonates; D005260:Female; D050723:Fractures, Bone; D006801:Humans; D007093:Imidazoles; D012306:Risk; D000077211:Zoledronic Acid
chemical_list: D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid